Condition
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 9 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATEDMechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantNCT01558778 · 2012-05-01
WITHDRAWNDeferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesNCT01273766 · 2011-01-01
COMPLETEDDeferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadNCT01159067 · 2010-07-01
TERMINATEDSunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyNCT00890747 · 2009-08-01
COMPLETEDOndansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantNCT00795769 · 2008-08-08
COMPLETEDLithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantNCT00408681 · 2006-06-01
COMPLETEDMonoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerNCT00039091 · 2002-03-01
TERMINATEDFludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerNCT00112593 · 1999-11-01
COMPLETEDCommon interventions
laboratory biomarker analysisOTHER4deferasiroxDRUG2IpilimumabBIOLOGICAL2management of therapy complicationsPROCEDURE2AbemaciclibDRUG1AbirateroneDRUG1AfatinibDRUG1BevacizumabBIOLOGICAL1BicalutamideDRUG1Biospecimen CollectionPROCEDURE1BortezomibDRUG1CabazitaxelDRUG1CabozantinibDRUG1CapecitabineDRUG1CarboplatinDRUG1CelecoxibDRUG1CobimetinibDRUG1CopanlisibDRUG1cyclosporineDRUG1DabrafenibDRUG1DacomitinibDRUG1DarolutamideDRUG1DasatinibDRUG1DoxorubicinDRUG1DurvalumabBIOLOGICAL1
Leading sponsors
Trial status mix
COMPLETED5
TERMINATED3
WITHDRAWN1
Phase mix
NA3
PHASE13
PHASE23
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.